Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

Anirban P. Mitra, Vikram M. Narayan, Sharada Mokkapati, Tanner Miest, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, J. Erik Busby, Michael Poch, Paul L. Crispen, Gary D. Steinberg, Anne K. Schuckman, Tracy M. Downs, Robert S. SvatekJoseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael E. Woods, Gordon A. Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O'Donnell, Richard Philipson, Seppo Ylä-Herttuala, David Sawutz, Nigel R. Parker, David J. McConkey, Colin P.N. DinneyShow 25 othersShow less